2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Somatostatin Receptor

Somatostatin Receptor

SSTRs; SSTR

Somatostatin Receptor

Related Products

PDF 0.61 MB

Somatostatin receptors (SSTR1, 2A and B, 3, 4 and 5) belong to the G protein coupled receptor family. Somatostatin receptors are expressed in a variety of human tumors, including most tumors of neuroendocrine origin, breast tumors, certain brain tumors, renal cell tumors, lymphomas, and prostate cancer. Somatostatin triggers cytostatic and cytotoxic effects and has a general inhibitory effect on secretion mediated through its interaction with somatostatin receptors.

The SSTRs 1-4 display weak selectivity for somatostatin-14 binding, whereas SSTR5 is somatostatin-28-selective. Based on structural similarity and reactivity for octapeptide and hexapeptide somatostatin receptor analogs, SSTRs 2, 3 and SSTR5 belong to a similar somatostatin receptor subclass; SSTRs 1-4 react poorly with these analogs and belong to a separate subclass. All five somatostatin receptors are functionally coupled to inhibition of adenylyl cyclase via pertussis toxin-sensitive guanosine triphosphate (GTP)-binding proteins. mRNA for SSTRs 1-5 is widely expressed in brain and peripheral organs and displays an overlapping but characteristic pattern that is subtype-selective and tissue- and species-specific. All pituitary cell subsets express SSTR2 and SSTR5, with SSTR5 being more abundant. Individual pituitary cells coexpress multiple somatostatin receptor subtypes.

Somatostatin Receptor Isoform Specific Products:

Somatostatin Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-106103A
    Seglitide acetate
    		Agonist 99.30%
    Seglitide acetate (MK 678; L 36358 acetate) is a potent, orally active somatostatin receptor 2 (SSTR2) agonist, and also a competitive antagonist of SSTR14, SSTR25, and SSTR28. Seglitide acetate has antihypertensive effects and can inhibit plasma glucagon and growth hormone. Seglitide acetate can be used for research on diabetes.
    Seglitide acetate
  • HY-P0024
    Veldoreotide
    		Activator
    Veldoreotide (DG3173) a somatostatin analogue, binds to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent
    Veldoreotide
  • HY-123499
    SRA880
    		Antagonist 98.22%
    SRA880 is a non-peptide and selective somatostatin sst(1) receptor antagonist. SRA880 exhibits antidepressant-like effects when in combination with Imipramine (HY-B1490A) .
    SRA880
  • HY-P5014
    Cortistatin-29 (human)
    		Modulator 98.48%
    Cortistatin-29 (human) is a somatostatin neuropeptide with potential for studying diseases such as cancer, inflammation, autoimmunity, fibrosis, and pain.
    Cortistatin-29 (human)
  • HY-P3899A
    [Nle8] Somatostatin (1-28) (TFA)
    		Chemical 99.86%
    [Nle8] Somatostatin (1-28) TFA is a derivative of somatosttin (1-28) with norleucine replacing methionine in position 8. [Nle8] Somatostatin (1-28) TFA increases the amylase release.[Nle8] Somatostatin (1-28) TFA increases the cyclic AMP in pancreatic acini .
    [Nle8] Somatostatin (1-28) (TFA)
  • HY-P5362A
    NODAGA-LM3 TFA
    		Antagonist
    NODAGA-LM3 TFA can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 TFA can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    NODAGA-LM3 TFA
  • HY-P3899
    [Nle8] Somatostatin (1-28)
    		Chemical
    [Nle8] Somatostatin (1-28) is a derivative of somatosttin (1-28) with norleucine replacing methionine in position 8. [Nle8] Somatostatin (1-28) increases the amylase release.[Nle8] Somatostatin (1-28) increases the cyclic AMP in pancreatic acini .
    [Nle8] Somatostatin (1-28)
  • HY-P4469
    PRL 3195
    		Antagonist
    PRL 3195 is a somatostatin receptor antagonist with Kis of 6, 17, 66, 1000 and 1000 nM for human somatostatin receptors (sst5, sst2, sst3, sst1 and sst4, respectively).
    PRL 3195
  • HY-114191
    SSTR5 antagonist 2
    		Antagonist
    SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM).
    SSTR5 antagonist 2
  • HY-114191A
    SSTR5 antagonist 2 TFA
    		Antagonist
    SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and selective somatostatin (receptor) subtype 5 (SSTR5) antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM).
    SSTR5 antagonist 2 TFA
  • HY-P2545
    [Tyr1]-Somatostatin-14
    [Tyr1]-Somatostatin-14 could binds to SSTR2.
    [Tyr1]-Somatostatin-14
  • HY-P4555
    (D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide
    		Agonist
    (D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide (Compound 4) is a somatostatin analog with Kds of 0.61, 11.05, 23.5, 1200 and >1000 nM for SSTR5, SSTR3, SSTR2, SSTR1 and SSTR4, respectively.
    (D-Phe5,Cys6,11,N-Me-D-Trp8)-Somatostatin-14 (5-12) amide
  • HY-142701
    SSTR4 agonist 4
    SSTR4 agonist 4 is a potent agonist of SSTR4. SSTR4 is expressed at relatively high levels in the hippocampus and neocortex, memory and learning regions, and Alzheimer's disease pathology. SSTR4 agonists are potent in rodent models of pain associated with acute and chronic associated anti-peripheral nociceptive and anti-inflammatory activity. SSTR4 agonist 4 has the potential for the research of pain (extracted from patent WO2021233428A1, compound 14).
    SSTR4 agonist 4
  • HY-RS13822
    Sstr1 Rat Pre-designed siRNA Set A
    		Inhibitor

    Sstr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sstr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Sstr1 Rat Pre-designed siRNA Set A
    Sstr1 Rat Pre-designed siRNA Set A
  • HY-125382
    L-797591
    		Agonist
    L-797591 is a selective somatostatin receptor subtype 1 (SSTR1) agonist.
    L-797591
  • HY-RS13830
    Sstr4 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Sstr4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Sstr4 Mouse Pre-designed siRNA Set A
    Sstr4 Mouse Pre-designed siRNA Set A
  • HY-RS13820
    SSTR1 Human Pre-designed siRNA Set A
    		Inhibitor

    SSTR1 Human Pre-designed siRNA Set A contains three designed siRNAs for SSTR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    SSTR1 Human Pre-designed siRNA Set A
    SSTR1 Human Pre-designed siRNA Set A
  • HY-RS13821
    Sstr1 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Sstr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Sstr1 Mouse Pre-designed siRNA Set A
    Sstr1 Mouse Pre-designed siRNA Set A
  • HY-RS13824
    Sstr2 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Sstr2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sstr2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Sstr2 Mouse Pre-designed siRNA Set A
    Sstr2 Mouse Pre-designed siRNA Set A
  • HY-P1203A
    BIM-23056 TFA
    		Antagonist
    BIM 23056 TFA, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with Ki values of 10.8, 5.7, respectively.
    BIM-23056 TFA
Cat. No. Product Name / Synonyms Application Reactivity
Somatostatin Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.